- Home
- FRME vs NVCR Comparison
FRME vs NVCR Comparison
Compare FRME & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRME
- NVCR
- Stock Information
- Founded
- FRME 1893
- NVCR 2000
- Country
- FRME United States
- NVCR Jersey
- Employees
- FRME N/A
- NVCR N/A
- Industry
- FRME Major Banks
- NVCR Medical/Dental Instruments
- Sector
- FRME Finance
- NVCR Health Care
- Exchange
- FRME Nasdaq
- NVCR Nasdaq
- Market Cap
- FRME 2.1B
- NVCR 1.8B
- IPO Year
- FRME N/A
- NVCR 2015
- Fundamental
- Price
- FRME $37.96
- NVCR $17.49
- Analyst Decision
- FRME Buy
- NVCR Buy
- Analyst Count
- FRME 5
- NVCR 5
- Target Price
- FRME $43.90
- NVCR $26.60
- AVG Volume (30 Days)
- FRME 248.8K
- NVCR 1.3M
- Earning Date
- FRME 10-24-2024
- NVCR 10-30-2024
- Dividend Yield
- FRME 3.78%
- NVCR N/A
- EPS Growth
- FRME N/A
- NVCR N/A
- EPS
- FRME 3.01
- NVCR N/A
- Revenue
- FRME $593,089,000.00
- NVCR $549,964,000.00
- Revenue This Year
- FRME N/A
- NVCR $16.23
- Revenue Next Year
- FRME $3.02
- NVCR $6.09
- P/E Ratio
- FRME $12.35
- NVCR N/A
- Revenue Growth
- FRME N/A
- NVCR 8.33
- 52 Week Low
- FRME $26.85
- NVCR $10.87
- 52 Week High
- FRME $42.45
- NVCR $24.74
- Technical
- Relative Strength Index (RSI)
- FRME 53.37
- NVCR 43.24
- Support Level
- FRME $35.13
- NVCR $15.61
- Resistance Level
- FRME $37.35
- NVCR $17.31
- Average True Range (ATR)
- FRME 1.17
- NVCR 1.29
- MACD
- FRME -0.06
- NVCR 0.05
- Stochastic Oscillator
- FRME 54.14
- NVCR 11.59
About FRME First Merchants Corporation
First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment which is community banking.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.